Mayne Pharma Group (AU:MYX)
ASX:MYX
Want to see AU:MYX full AI Analyst Report?
MYX Stock Chart & Stats
AU$6.01
-AU$0.13(-2.74%)
At close: 4:00 PM EST
AU$6.01
-AU$0.13(-2.74%)
Day’s Range― - ―
52-Week RangeAU$2.04 - AU$6.50
Previous CloseN/A
Volume149.18K
Average Volume (3M)593.75K
Market Cap
AU$191.74M
Enterprise ValueAU$167.39M
Total Cash (Recent Filing)AU$67.35M
Total Debt (Recent Filing)AU$44.62M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 20, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding81,245,830
10 Day Avg. Volume776,050
30 Day Avg. Volume593,750
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross Margin And MixA ~3.9ppt gross margin uplift reflects a sustainably higher-quality product mix and better margin control. Higher gross margins provide durable earnings leverage versus revenue volatility, supporting reinvestment in branded franchises and cushioning operating margins over the next 2-6 months.
Dermatology Margin-Led TurnaroundDermatology's shift to a higher branded mix materially raised direct contribution, creating a structurally higher-margin segment. This provides a more stable cash-generative business line, improving portfolio resilience and funding for marketing or targeted M&A over the medium term.
Strong Liquidity And Low LeverageA cash balance of ~$67m combined with low reported debt-to-equity (~0.11) gives the company financial flexibility. This liquidity supports litigation costs, capex (Salisbury upgrade), selective investments, or buybacks while limiting refinancing risk over the coming 2-6 months.
Bears Say
Negative Profitability And Declining RevenuePersistent negative margins and slight revenue decline signal structural profitability weakness. Until margins convert to positive operating earnings, the business will struggle to generate sustainable shareholder returns and improve ROE, constraining long-term reinvestment capacity.
Poor Cash Conversion And FCF DeteriorationSeverely impaired free cash flow growth and weak conversion of earnings into cash reduce operational flexibility. This limits capacity to fund marketing, capex, or defend against competitive pressures without using cash reserves or raising capital, a durable constraint on strategy execution.
Ongoing Litigation And One-Off ChargesMaterial litigation, earn-out reassessments and transaction costs create persistent cash outflow and earnings volatility. Legal uncertainty can drain management attention, deter partners, and complicate capital allocation decisions, presenting a multi‑quarter structural risk to execution.
Mayne Pharma Group News
MYX FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest share price was AU$2.04 and its highest was AU$6.50 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is AU$191.74M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 58 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -AU$0.15 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.15.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Overvalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of AU$0.544 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate is -0.3.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -AU$0.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.783%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in AU:MYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Ltd. operates as a specialized pharmaceutical enterprise, dedicated to the global production and distribution of both proprietary (branded) and unbranded (generic) medicinal products. Its extensive market reach spans Australia, New Zealand, North America (the United States and Canada), Europe, and Asia. The company's business activities are organized across four distinct divisions: Metrics Contract Services, International, Branded Products, and Portfolio Products. Mayne Pharma offers innovative oral drug delivery technologies and provides comprehensive contract services, including pharmaceutical development, manufacturing, and analytical support to external clients. Furthermore, the firm specializes in the distribution of pharmaceutical products tailored for key therapeutic areas such as dermatology, women's health, and infectious diseases. Incorporated in 2005, and headquartered in Salisbury South, Australia, the company was formerly known as Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010.
MYX Company Deck
MYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all AU:MYX earnings summariesTechnical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---